(VIANEWS) – Chesapeake Utilities Corporation (CPK), Evercore Partners (EVR), Amgen (AMGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Chesapeake Utilities Corporation (CPK)
37.2% sales growth and 9.07% return on equity
Chesapeake Utilities Corporation operates as an energy delivery company. The Regulated Energy segment engages in the natural gas distribution operations in central and southern Delaware, Maryland's eastern shore, and Florida; regulated natural gas transmission in the Delmarva Peninsula and Florida; and regulated electric distribution in northeast and northwest Florida. The Unregulated Energy segment engages in the propane operations in the Mid-Atlantic region and Florida; unregulated natural gas transmission/supply operation in central and eastern Ohio; generation of electricity and steam; and provision of compressed natural gas, liquefied natural gas, and renewable natural gas transportation and pipeline solutions primarily to utilities and pipelines in the eastern United States. This segment also provides other unregulated energy services, such as energy-related merchandise sales; heating, ventilation, and air conditioning services; and plumbing and electrical services. The company was founded in 1859 and is headquartered in Dover, Delaware.
Earnings Per Share
As for profitability, Chesapeake Utilities Corporation has a trailing twelve months EPS of $4.76.
PE Ratio
Chesapeake Utilities Corporation has a trailing twelve months price to earnings ratio of 22.66. Meaning, the purchaser of the share is investing $22.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.07%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 2.56 and the estimated forward annual dividend yield is 2.41%.
Moving Average
Chesapeake Utilities Corporation’s worth is under its 50-day moving average of $108.25 and above its 200-day moving average of $102.17.
Sales Growth
Chesapeake Utilities Corporation’s sales growth is 23% for the present quarter and 37.2% for the next.
Yearly Top and Bottom Value
Chesapeake Utilities Corporation’s stock is valued at $107.87 at 20:22 EST, way under its 52-week high of $124.72 and way higher than its 52-week low of $83.80.
2. Evercore Partners (EVR)
30.8% sales growth and 17.78% return on equity
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Evercore Partners has a trailing twelve months EPS of $6.41.
PE Ratio
Evercore Partners has a trailing twelve months price to earnings ratio of 32.98. Meaning, the purchaser of the share is investing $32.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.78%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.5%, now sitting on 2.43B for the twelve trailing months.
Yearly Top and Bottom Value
Evercore Partners’s stock is valued at $211.41 at 20:22 EST, under its 52-week high of $213.20 and way higher than its 52-week low of $117.16.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 72.9% and 89.2%, respectively.
Volume
Today’s last reported volume for Evercore Partners is 381854 which is 14.15% above its average volume of 334503.
3. Amgen (AMGN)
22.2% sales growth and 72.57% return on equity
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.48.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.42. Meaning, the purchaser of the share is investing $21.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.57%.
Moving Average
Amgen’s value is way under its 50-day moving average of $303.26 and under its 200-day moving average of $285.91.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 0.6% and positive 4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22%, now sitting on 29.53B for the twelve trailing months.
Volume
Today’s last reported volume for Amgen is 1865240 which is 36.92% below its average volume of 2957370.
Previous days news about Amgen(AMGN)
- According to Zacks on Friday, 12 July, "In May, Amgen said it was "very encouraged" with the interim data from the phase II study on MariTide. "
4. Hercules Technology Growth Capital (HTGC)
10.4% sales growth and 19.73% return on equity
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.2.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 9.63. Meaning, the purchaser of the share is investing $9.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.73%.
Yearly Top and Bottom Value
Hercules Technology Growth Capital’s stock is valued at $21.18 at 20:22 EST, under its 52-week high of $21.19 and way higher than its 52-week low of $14.62.
Sales Growth
Hercules Technology Growth Capital’s sales growth is 16.3% for the current quarter and 10.4% for the next.
5. LeMaitre Vascular (LMAT)
10.4% sales growth and 11.65% return on equity
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.51.
PE Ratio
LeMaitre Vascular has a trailing twelve months price to earnings ratio of 55.38. Meaning, the purchaser of the share is investing $55.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.65%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 30.6% and 27.3%, respectively.
Volume
Today’s last reported volume for LeMaitre Vascular is 73174 which is 43.24% below its average volume of 128931.
6. Synopsys (SNPS)
8.6% sales growth and 21.58% return on equity
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, MIPI, HDMI, and Bluetooth low energy applications; logic libraries and embedded memories; processor cores, software, and application-specific instruction-set processor tools for embedded applications; security IP solutions; IP solutions for automotive market; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers HAPS FPGA-based prototyping systems; virtual prototyping solutions; and Platform Architect solutions for SoC architecture analysis and optimization, as well as optical products, and mechatronic simulations. Further, it provides security and quality testing products, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. Additionally, the company provides intelligent orchestration solution, software risk manager, and black duck software composition analysis tools. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Synopsys has a trailing twelve months EPS of $9.04.
PE Ratio
Synopsys has a trailing twelve months price to earnings ratio of 61.63. Meaning, the purchaser of the share is investing $61.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.58%.
Previous days news about Synopsys(SNPS)
- Brokers suggest investing in synopsys (snps): read this before placing a bet. According to Zacks on Thursday, 11 July, "Let’s take a look at what these Wall Street heavyweights have to say about Synopsys (SNPS Quick QuoteSNPS – Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.", "Check price target & stock forecast for Synopsys here>>>The ABR suggests buying Synopsys, but making an investment decision solely on the basis of this information might not be a good idea. "
7. CONMED Corporation (CNMD)
8.4% sales growth and 10.25% return on equity
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Earnings Per Share
As for profitability, CONMED Corporation has a trailing twelve months EPS of $2.61.
PE Ratio
CONMED Corporation has a trailing twelve months price to earnings ratio of 26.38. Meaning, the purchaser of the share is investing $26.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.25%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.7%, now sitting on 1.26B for the twelve trailing months.
Yearly Top and Bottom Value
CONMED Corporation’s stock is valued at $68.86 at 20:22 EST, way under its 52-week high of $137.86 and way above its 52-week low of $61.05.
Moving Average
CONMED Corporation’s value is under its 50-day moving average of $71.47 and way under its 200-day moving average of $88.67.
Volume
Today’s last reported volume for CONMED Corporation is 366114 which is 26.76% below its average volume of 499949.
8. WillScot Mobile Mini Holdings Corp. (WSC)
7% sales growth and 22.32% return on equity
WillScot Mobile Mini Holdings Corp. provides modular space and portable storage solutions in the United States, Canada, Mexico, and the United Kingdom. The company leases various office space and storage solutions for temporary applications across a customer base in the commercial and industrial, construction, retail, education, health care, government, transportation, security, and energy sectors. . It operates a fleet of over 350,000 portable offices and storage containers. The company is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, WillScot Mobile Mini Holdings Corp. has a trailing twelve months EPS of $1.62.
PE Ratio
WillScot Mobile Mini Holdings Corp. has a trailing twelve months price to earnings ratio of 23.23. Meaning, the purchaser of the share is investing $23.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.32%.
